Chronic exposure to a β2-adrenoceptor agonist increases the airway response to methacholine

Paula A. Witt-Enderby, Henry I. Yamamura, Marilyn Halonen, John D. Palmer, John W Bloom

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Scheduled chronic administration of β2-adrenoceptor agonist bronchodilators in patients with asthma recently has been reported to be associated with a worsening of symptoms and an increase in bronchial responsiveness. We wanted to determine whether a 28-day in vivo exposure to albuterol (β2-adrenoceptor agonist) altered the response of rabbit airways to the cholinergic agonist methacholine. We found, using in vitro tissue bath techniques, that in mainstem bronchi from rabbits given a 28-day exposure to albuterol, maximum contraction to methacholine was increased in the albuterol-treated group (control group = 1.10 ± 0.11 g vs. treated group = 1.50 ± 0.13 g, P < 0.05). The potency (EC75) was also increased in the albuterol-treated group. The potency for the control group was 5.6 μM (95% confidence limit: 2.3-13 μM) and was 1.7 μM (95% confidence limit: 1.1-2.8 μM, P < 0.05) for the albuterol-treated group. In a subgroup of animals, maximum contraction to KCl, a receptor-independent contractile stimulus, was not significantly different between the groups (control group = 0.79 ± 0.23 g vs. treated group = 0.82 ± 0.20 g). The potency (EC50) for KCl-induced contractions was also not significantly different between the groups: control = 12 mM (95% confidence limit: 3.3-44 mM) vs. treated 19 mM (95% confidence limit: 18-20 mM). These data demonstrate that chronic in vivo exposure to a β2-adrenoceptor agonist can alter the in vitro tissue bath response of airway smooth muscle to methacholine. Therefore, cholinergic mechanisms in the airway smooth muscle appear to be altered by chronic β2-adrenoceptor agonist exposure. This change in the airway smooth muscle response to methacholine may play a role in the increase of bronchial responsiveness associated with regular β2-adrenoceptor agonist use.

Original languageEnglish (US)
Pages (from-to)121-123
Number of pages3
JournalEuropean Journal of Pharmacology
Volume241
Issue number1
DOIs
StatePublished - Sep 7 1993

Fingerprint

Methacholine Chloride
Albuterol
Adrenergic Receptors
Smooth Muscle
Control Groups
Baths
Rabbits
Cholinergic Agonists
Bronchodilator Agents
Bronchi
Cholinergic Agents
Asthma

Keywords

  • (Rabbit)
  • Albuterol
  • Asthma
  • Methacholine
  • β-Adrenoceptor agonists

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Chronic exposure to a β2-adrenoceptor agonist increases the airway response to methacholine. / Witt-Enderby, Paula A.; Yamamura, Henry I.; Halonen, Marilyn; Palmer, John D.; Bloom, John W.

In: European Journal of Pharmacology, Vol. 241, No. 1, 07.09.1993, p. 121-123.

Research output: Contribution to journalArticle

Witt-Enderby, Paula A. ; Yamamura, Henry I. ; Halonen, Marilyn ; Palmer, John D. ; Bloom, John W. / Chronic exposure to a β2-adrenoceptor agonist increases the airway response to methacholine. In: European Journal of Pharmacology. 1993 ; Vol. 241, No. 1. pp. 121-123.
@article{1166c811856345dc8088952f369c6b01,
title = "Chronic exposure to a β2-adrenoceptor agonist increases the airway response to methacholine",
abstract = "Scheduled chronic administration of β2-adrenoceptor agonist bronchodilators in patients with asthma recently has been reported to be associated with a worsening of symptoms and an increase in bronchial responsiveness. We wanted to determine whether a 28-day in vivo exposure to albuterol (β2-adrenoceptor agonist) altered the response of rabbit airways to the cholinergic agonist methacholine. We found, using in vitro tissue bath techniques, that in mainstem bronchi from rabbits given a 28-day exposure to albuterol, maximum contraction to methacholine was increased in the albuterol-treated group (control group = 1.10 ± 0.11 g vs. treated group = 1.50 ± 0.13 g, P < 0.05). The potency (EC75) was also increased in the albuterol-treated group. The potency for the control group was 5.6 μM (95{\%} confidence limit: 2.3-13 μM) and was 1.7 μM (95{\%} confidence limit: 1.1-2.8 μM, P < 0.05) for the albuterol-treated group. In a subgroup of animals, maximum contraction to KCl, a receptor-independent contractile stimulus, was not significantly different between the groups (control group = 0.79 ± 0.23 g vs. treated group = 0.82 ± 0.20 g). The potency (EC50) for KCl-induced contractions was also not significantly different between the groups: control = 12 mM (95{\%} confidence limit: 3.3-44 mM) vs. treated 19 mM (95{\%} confidence limit: 18-20 mM). These data demonstrate that chronic in vivo exposure to a β2-adrenoceptor agonist can alter the in vitro tissue bath response of airway smooth muscle to methacholine. Therefore, cholinergic mechanisms in the airway smooth muscle appear to be altered by chronic β2-adrenoceptor agonist exposure. This change in the airway smooth muscle response to methacholine may play a role in the increase of bronchial responsiveness associated with regular β2-adrenoceptor agonist use.",
keywords = "(Rabbit), Albuterol, Asthma, Methacholine, β-Adrenoceptor agonists",
author = "Witt-Enderby, {Paula A.} and Yamamura, {Henry I.} and Marilyn Halonen and Palmer, {John D.} and Bloom, {John W}",
year = "1993",
month = "9",
day = "7",
doi = "10.1016/0014-2999(93)90942-B",
language = "English (US)",
volume = "241",
pages = "121--123",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Chronic exposure to a β2-adrenoceptor agonist increases the airway response to methacholine

AU - Witt-Enderby, Paula A.

AU - Yamamura, Henry I.

AU - Halonen, Marilyn

AU - Palmer, John D.

AU - Bloom, John W

PY - 1993/9/7

Y1 - 1993/9/7

N2 - Scheduled chronic administration of β2-adrenoceptor agonist bronchodilators in patients with asthma recently has been reported to be associated with a worsening of symptoms and an increase in bronchial responsiveness. We wanted to determine whether a 28-day in vivo exposure to albuterol (β2-adrenoceptor agonist) altered the response of rabbit airways to the cholinergic agonist methacholine. We found, using in vitro tissue bath techniques, that in mainstem bronchi from rabbits given a 28-day exposure to albuterol, maximum contraction to methacholine was increased in the albuterol-treated group (control group = 1.10 ± 0.11 g vs. treated group = 1.50 ± 0.13 g, P < 0.05). The potency (EC75) was also increased in the albuterol-treated group. The potency for the control group was 5.6 μM (95% confidence limit: 2.3-13 μM) and was 1.7 μM (95% confidence limit: 1.1-2.8 μM, P < 0.05) for the albuterol-treated group. In a subgroup of animals, maximum contraction to KCl, a receptor-independent contractile stimulus, was not significantly different between the groups (control group = 0.79 ± 0.23 g vs. treated group = 0.82 ± 0.20 g). The potency (EC50) for KCl-induced contractions was also not significantly different between the groups: control = 12 mM (95% confidence limit: 3.3-44 mM) vs. treated 19 mM (95% confidence limit: 18-20 mM). These data demonstrate that chronic in vivo exposure to a β2-adrenoceptor agonist can alter the in vitro tissue bath response of airway smooth muscle to methacholine. Therefore, cholinergic mechanisms in the airway smooth muscle appear to be altered by chronic β2-adrenoceptor agonist exposure. This change in the airway smooth muscle response to methacholine may play a role in the increase of bronchial responsiveness associated with regular β2-adrenoceptor agonist use.

AB - Scheduled chronic administration of β2-adrenoceptor agonist bronchodilators in patients with asthma recently has been reported to be associated with a worsening of symptoms and an increase in bronchial responsiveness. We wanted to determine whether a 28-day in vivo exposure to albuterol (β2-adrenoceptor agonist) altered the response of rabbit airways to the cholinergic agonist methacholine. We found, using in vitro tissue bath techniques, that in mainstem bronchi from rabbits given a 28-day exposure to albuterol, maximum contraction to methacholine was increased in the albuterol-treated group (control group = 1.10 ± 0.11 g vs. treated group = 1.50 ± 0.13 g, P < 0.05). The potency (EC75) was also increased in the albuterol-treated group. The potency for the control group was 5.6 μM (95% confidence limit: 2.3-13 μM) and was 1.7 μM (95% confidence limit: 1.1-2.8 μM, P < 0.05) for the albuterol-treated group. In a subgroup of animals, maximum contraction to KCl, a receptor-independent contractile stimulus, was not significantly different between the groups (control group = 0.79 ± 0.23 g vs. treated group = 0.82 ± 0.20 g). The potency (EC50) for KCl-induced contractions was also not significantly different between the groups: control = 12 mM (95% confidence limit: 3.3-44 mM) vs. treated 19 mM (95% confidence limit: 18-20 mM). These data demonstrate that chronic in vivo exposure to a β2-adrenoceptor agonist can alter the in vitro tissue bath response of airway smooth muscle to methacholine. Therefore, cholinergic mechanisms in the airway smooth muscle appear to be altered by chronic β2-adrenoceptor agonist exposure. This change in the airway smooth muscle response to methacholine may play a role in the increase of bronchial responsiveness associated with regular β2-adrenoceptor agonist use.

KW - (Rabbit)

KW - Albuterol

KW - Asthma

KW - Methacholine

KW - β-Adrenoceptor agonists

UR - http://www.scopus.com/inward/record.url?scp=0027182329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027182329&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(93)90942-B

DO - 10.1016/0014-2999(93)90942-B

M3 - Article

C2 - 7901034

AN - SCOPUS:0027182329

VL - 241

SP - 121

EP - 123

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -